Abstract:Background A severe deficiency of ADAMTS13 activity contributes to the pathogenesis of thrombotic thrombocytopenic purpura (TIP). Measuring the activity of ADAMTS13 is helpful for the diagnosis of UP and the prognostic monitor in TIP patients. Most available assays are cumbersome and costly, so not easily adapted to routine laboratories. ADAMTS13 cleaves von Willebrand factor (VWF) within the domain A2, located between domains Al and A3. Therefore, specific assays for ADAMTS13 activity could be based on the different structures of VWF before and after the cleavage. Using this hypothesis we try to establish a new and simple method to determine ADAMTS13 activity.Methods First, plasma samples were exposed in denaturing condition to allow cleavage of VWF by ADAMTS13. Then, the ADAMTS13 activity was measured with two novel monoclonal antibodies, SZ-129 and SZ-125, which specifically recognize the VWF Al and A3 domains by using a two-site sandwich ELISA. Compared with a residual-collagen binding assay (R-CBA), plasma ADAMTS13 activities in 161 samples were assessed, and the inhibitory activities of ADAMTS13 autoantibody in 24 TIP patients were determined. The relationship of these two assays was analyzed by linear correlation, and the sensitivity and specificity of the new assay was also evaluated.Results Plasma ADAMTS13 activities in normal people and TIP, acute myocardial infarction (AMI), and idiopathic thrombocytopenic purpura (ITP) patients determined by the new assay were (89.75 +/- 7.93)%, (17.63 +/- 18.71)%, (68.55 +/- 18.08)%, (85.83 +/- 9.84)%, respectively. Results were consistent with those of R-CBA, the squared correlation factor was 0.9183 of the two assays. The new assay can easily discriminate a UP plasma sample from a non-TIP plasma sample (P <0.01), and the coefficient of variation for the new assay was 6.17%. In 23 idiopathic UP patients, the inhibitor activity of ADAMTS13 autoantibody ranged from 12% to 100%, while no inhibitory activity was detected in one hereditary UP patient.Conclusion This new and simple assay for ADAMTS13 activity could be used routinely in the clinic to determine the activity of ADAMTS13. Chin Med J 2010;123(14):1859-1863

Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity

[Stable Expression and Characterization of the Von Willebrand Factor Cleaving Protease].

[Research on the C-terminal Domain of ADAMTS13 Regulates Its Cleaving Activity].

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

Evaluation and Clinical Application of A New Method for Detecting Adamts13 Activity

Expression, Purification and Characterization of Recombinant Human Coagulation Factor XIIIa in Pichia Pastoris

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura

The effect of ADAMTS13 on graft-versus-host disease

Therapy of Hereditary Ttp with Adamts13 Deficiency - A Case Report and Review of the Literature.

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13

Mechanistic studies on ADAMTS13 catalysis

The Highs and Lows of ADAMTS13 Activity

Recombinant ADAMTS13 Reduces Tissue Plasminogen Activator‐induced Hemorrhage after Stroke in Mice

A comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)

The Development of Monoclonal Anti-Adamts18 Antibodies with Precise Validation of ADAMTS18 Post-Translational Modification Status in Living Organisms.

The expression of ADAMTS13 in human microvascular endothelial cells.

Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 Activity in Caplacizumab-Treated Japanese iTTP Patients

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura